Market Research Logo

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015

Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015’, provides an overview of the Refractory Acute Myeloid Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Refractory Acute Myeloid Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Refractory Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Refractory Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Refractory Acute Myeloid Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Refractory Acute Myeloid Leukemia Overview
Therapeutics Development
Pipeline Products for Refractory Acute Myeloid Leukemia - Overview
Pipeline Products for Refractory Acute Myeloid Leukemia - Comparative Analysis
Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies
Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes
Refractory Acute Myeloid Leukemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Refractory Acute Myeloid Leukemia - Products under Development by Companies
Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes
Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Conkwest, Inc.
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Daiichi Sankyo Company, Limited
Eisai Co., Ltd.
EpiZyme, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Fujifilm Corporation
GlaxoSmithKline Plc
Igenica Biotherapeutics, Inc.
Incyte Corporation
Jiangsu Hansoh Pharmaceutical Co., Ltd.
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
MacroGenics, Inc.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Oxford BioTherapeutics Ltd
Pharma Mar, S.A.
Pharmacyclics, Inc.
Plexxikon Inc.
Polaris Pharmaceuticals, Inc.
Seattle Genetics, Inc.
SpectraMab GmbH
Sunesis Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
TaiGen Biotechnology Co., Ltd.
Threshold Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Verastem, Inc.
Refractory Acute Myeloid Leukemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4SC-202 - Drug Profile
AG-120 - Drug Profile
alvocidib hydrochloride - Drug Profile
AMG-232 - Drug Profile
AT-9283 - Drug Profile
BI-836858 - Drug Profile
binimetinib - Drug Profile
bortezomib - Drug Profile
brentuximab vedotin - Drug Profile
burixafor - Drug Profile
cabozantinib s-malate - Drug Profile
cafusertib hydrochloride - Drug Profile
CB-839 - Drug Profile
CC-90007 - Drug Profile
Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile
Cell Therapy to Target CD33 for Acute Myeloid Leukemia - Drug Profile
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile
CPI-613 - Drug Profile
crenolanib besylate - Drug Profile
CST-101 - Drug Profile
CWP-291 - Drug Profile
DFP-10917 - Drug Profile
DS-3032 - Drug Profile
E-6201 - Drug Profile
elesclomol - Drug Profile
eltrombopag olamine - Drug Profile
EPZ-5676 - Drug Profile
erlotinib hydrochloride - Drug Profile
evofosfamide - Drug Profile
FF-10501 - Drug Profile
ficlatuzumab - Drug Profile
FLX-925 - Drug Profile
gilteritinib fumarate - Drug Profile
GO-2032c - Drug Profile
GSK-2879552 - Drug Profile
GSK-525762 - Drug Profile
huCART19 - Drug Profile
ibrutinib - Drug Profile
IGN-523 - Drug Profile
ilorasertib - Drug Profile
imatinib mesylate - Drug Profile
indisulam - Drug Profile
Iomab-B - Drug Profile
KHK-2823 - Drug Profile
lenalidomide - Drug Profile
lirilumab - Drug Profile
lurbinectedin - Drug Profile
MGD-006 - Drug Profile
midostaurin - Drug Profile
MK-2206 - Drug Profile
OPB-51602 - Drug Profile
Oshadi D + Oshadi R - Drug Profile
OX-001 - Drug Profile
pegargiminase - Drug Profile
PIM-447 - Drug Profile
PLX-3397 - Drug Profile
quizartinib dihydrochloride - Drug Profile
RG-7775 - Drug Profile
ruxolitinib phosphate - Drug Profile
S-055746 - Drug Profile
selinexor - Drug Profile
selumetinib sulfate - Drug Profile
TAK-659 - Drug Profile
temozolomide - Drug Profile
TEN-010 - Drug Profile
tigecycline - Drug Profile
tosedostat - Drug Profile
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Triplebody 19x16x19 - Drug Profile
ulocuplumab - Drug Profile
venetoclax - Drug Profile
vorinostat - Drug Profile
vosaroxin - Drug Profile
VS-4718 - Drug Profile
Refractory Acute Myeloid Leukemia - Recent Pipeline Updates
Refractory Acute Myeloid Leukemia - Dormant Projects
Refractory Acute Myeloid Leukemia - Discontinued Products
Refractory Acute Myeloid Leukemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2015
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Astex Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Conkwest, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar, S.A., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Pharmacyclics, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by SpectraMab GmbH, H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Synta Pharmaceuticals Corp., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015
Refractory Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Refractory Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2015
Refractory Acute Myeloid Leukemia - Dormant Projects, H1 2015
Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H1 2015
Refractory Acute Myeloid Leukemia - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Refractory Acute Myeloid Leukemia, H1 2015
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report